Drug Pipeline Tracker
Monitor breakthrough therapies from preclinical to FDA approval
8 Drugs in Pipeline
IMB-7200
Immunoblade
Indication
Severe Atopic Dermatitis
Mechanism of Action
JAK1 Selective Inhibitor
Q1 2025
800
81%
$3.3B
BRX-1142
BrainRx Therapeutics
Indication
Treatment-Resistant Depression
Mechanism of Action
NMDA Receptor Modulator
Q1 2025
Completed
88%
$2.9B
CAR-512
CellGen Bio
Indication
B-Cell Acute Lymphoblastic Leukemia
Mechanism of Action
Next-Gen CAR-T Cell Therapy
Q1 2026
150
72%
$2.1B
ONX-4021
Onyx Therapeutics
Indication
Non-Small Cell Lung Cancer
Mechanism of Action
PD-L1/VEGF Bispecific Antibody
Q2 2025
1,200
68%
$4.2B
ONC-3917
OncoNext
Indication
Triple-Negative Breast Cancer
Mechanism of Action
TROP2-Directed ADC
Q2 2027
35
35%
$3.1B
CVX-089
CardioVex
Indication
Heart Failure with Preserved Ejection Fraction
Mechanism of Action
SGLT2/GLP-1 Dual Agonist
Q3 2025
3,500
62%
$5.8B
RDX-4729
Radix Pharmaceuticals
Indication
Duchenne Muscular Dystrophy
Mechanism of Action
Gene Therapy (AAV-Microdystrophin)
Q3 2026
48
58%
$1.5B
NRX-101
NeuroRx Pharma
Indication
Alzheimer's Disease (Early Stage)
Mechanism of Action
Tau Protein Aggregation Inhibitor
Q4 2025
2,100
45%
$8.7B
Pipeline Analytics
Key insights from our drug development tracker
Average Phase III Success Rate
Expected Approvals 2025
Total Market Opportunity
Breakthrough Designations
Get Pipeline Updates
Receive weekly alerts on drug developments in your areas of interest